A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease

Phase 2 Withdrawn Janssen Research & Development, LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of JNJ-64304500 as add-on therapy to standard of care (SOC) biologic treatment with anti-tumor necrosis factor alpha or anti-interleukin 12/23 inhibitors in participants with active Crohn's disease in response but not remission to SOC biologic therapy.

Timeline

Start: 2021-03-03
Primary completion: 2023-05-24
Completion: 2023-09-04

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision.”

Publications

Hasskamp J, Meinhardt C, Timmer A. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2025 May 13;5(5):CD007572. doi: 10.1002/14651858.CD007572.pub4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JNJ-64304500	Unknown	—	Subcutaneous
Background	Adalimumab	Monoclonal antibody	—	—
Background	Ustekinumab	Monoclonal antibody	—	—